

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Austin L. Gurney et al. Serial No.: not yet assigned Filed: December 11, 2003	Group Art Unit: not yet assigned Examiner: not yet assigned CUSTOMER NO: 09157
For: Novel Inhibitor of Hepatocyte Growth Factor Activator for Use in Modulation of Angiogenesis and Cardiovascularization	Express Mail Label No. EV 351928194US December 11, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of

Serial No. not yet assigned

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/742,201, filed December 19, 2000 and relied upon in this application for an earlier filing date under 35 USC §120.

Serial No.: not yet assigned
Filed: December 11, 2003

Page 3

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: December 11, 2003

By: 

Paul Naik, Ph.D.

Reg. No. 49,075

Telephone No. (650) 225-5530

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1		Serial No. not yet assigned	
				Applicant Austin L. Gurney et al.			
				Filing Date 11 Dec 2003			
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	4,736,866	12.04.88	Leder et al.			
	* 2	4,873,191	10.10.89	Wagner et al.			
	* 3	5,573,762	12.11.96	Ferrara et al.			
	* 4	5,610,134	11.03.97	Clark et al.			
	* 5	5,624,806	29.04.97	Baker et al.			
	* 6	5,650,282	22.07.97	Keating et al.			
	* 7	5,661,122	26.08.97	Clark et al.			
	* 8	5,773,223	30.06.98	Shyamala et al.			
	* 9	5,773,414	30.06.98	Cody et al.			
	* 10	5,935,924	10.08.99	Bunting et al.			
	* 11	6,225,081		Shimomura et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	* 12	0 759 467 A	26.02.97	EPO			
	* 13	370,989 B1	04.09.96	EPO			
	* 14	457,195 B1	15.04.98	EPO			
	* 15	460,679 B1	28.10.98	EPO			
	* 16	471,754 B1	31.07.96	EPO			
	* 17	552,489 B1	04.03.98	EPO			
	* 18	3130299	04.06.91	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	* 19	WO 89/06692	27.07.89	PCT			
	* 20	WO 91/01753	21.02.91	PCT			
	* 21	WO 91/07491	30.05.91	PCT			
	* 22	WO 92/22653	23.12.92	PCT			
	* 23	WO 95/05846	02.03.95	PCT			
	* 24	WO 95/16035	15.06.95	PCT			
	* 25	WO 95/28173	26.10.95	PCT			
	* 26	WO 96/17931	13.06.96	PCT			
	* 27	WO 96/30046	03.10.96	PCT			
	* 28	WO 97/33551	18.09.97	PCT			
	* 29	WO 98/45331	15.10.98	PCT			
	* 30	WO 98/45332	15.10.98	PCT			
	* 31	01/05972 A1	25.01.01	WO			
	* 32	97/12629	10.04.97	WO			
Examiner					Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*	33	Adamis et al., "Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate" <u>Arch. Ophthalmology</u> 114(1):66-71 (1996)			
*	34	Aiello et al., "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders" <u>New England J. of Medicine</u> 331(22):1480-1487 (1994)			
*	35	Berkman et al., "Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms" <u>J. Clin. Invest.</u> 91(1):153-159 (1993)			
*	36	Betocchi et al., "Effects of Diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy" <u>Am. J. Cardiol.</u> 78:451-457 (1996)			
*	37	Beznak, M. <u>Can. J. Biochem. Physiol.</u> 33:985-994 (1955)			
*	38	Bonow et al., "Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects" <u>Circulation</u> 72:853-864 (1985)			
*	39	Borgstrom et al., "Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy" <u>Cancer Research</u> 56(17):4032-4039 (1996)			
*	40	Bradham et al., "Connective Tissue Growth Factor: a Cysteine-rich Mitogen Secreted by Human Vascular Endothelial Cells Is Related to the SRC-induced Immediate Early Gene Product CEF-10" <u>Journal of Cell Biology</u> 114:1285-1294 (1991)			
*	41	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)			
*	42	Brown and Vaughan, "Angiotensin-Converting Enzyme Inhibitors" <u>Circulation</u> 97:1411-1420 (1998)			
*	43	Brown et al., "Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract" <u>Cancer Research</u> 53(19):4727-4735 (1993)			
*	44	Brown et al., "Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer" <u>Human Pathology</u> 26(1):86-91 (1995)			
*	45	Burgess and Maciag, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins" <u>Annu. Rev. Biochem.</u> 58:575-606 (1989)			
*	46	The Captopril Multicenter Research Group, "A Placebo-Controlled Trial of Captopril in Refractory Chronic Congestive Heart Failure" <u>JACC</u> 2(4):755-763 (1983)			
*	47	The Captopril-Digoxin Multicenter Research Group, "Comparative Effects of Therapy with Captopril and Digoxin in Patients with Mild to Moderate Heart Failure" <u>Journal of the American Medical Assn.</u> 259(4):539-544 (1988)			
*	48	Cheng et al., "Relationship between the inhibition constant (K_I) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction" <u>Biochem. Pharmacol.</u> 22:3099-3108 (1973)			
*	49	Chien et al., "Regulation of Cardiac Gene Expression During Myocardial Growth and Hypertrophy: Molecular Studies of an Adaptive Physiologic Response" <u>FASEB Journal</u> 5:3037-3046 (1991)			
*	50	Chien et al., "Transcriptional Regulation During Cardiac Growth and Development" <u>Annu. Rev. Physiol.</u> 55:77-95 (1993)			
*	51	Clapp et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis" <u>Endocrinology</u> 133(3):1292-1299 (1993)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*	52	Clemmons et al., "Cultured Fibroblast Monolayers Secrete a Protein That Alters the Cellular Binding of Somatomedin-C/Insulinlike Growth Factor I" <u>J. Clin. Invest.</u> 77:1548-1556 (1986)			
*	53	Cohn et al., "A Comparison of Enalapril with Hydralazine-Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure" <u>New England J. of Medicine</u> 325(5):303-310 (1991)			
*	54	Connolly et al., "Human Vascular Permeability Factor" <u>Journal of Biological Chemistry</u> 264(33):20017-20024 (1989)			
*	55	The CONSENSUS Trial Study Group, "Effects of Enalapril on Mortality in Severe Congestive Heart Failure" <u>New England J. of Medicine</u> 316(23):1429-1435 (1987)			
*	56	DeLeo et al., "Cell Surface Antigens of Chemically Induced Sarcomas of the Mouse" <u>Journal of Experimental Medicine</u> 146:720-734 (1977)			
*	57	Drebin et al., "Inhibition of Tumor Growth By a Monoclonal Antibody Reactive With an Oncogene-Encoded Tumor Antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)			
*	58	Dunn et al., "The Cleavage and Formation of Activated Human Hageman Factor by Autodigestion and by Kallikrein" <u>Journal of Biological Chemistry</u> 257:1779-1784 (1982)			
*	59	Dvorak et al., "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis" <u>American Journal of Pathology</u> 146(5):1029-1039 (1995)			
*	60	Eaglstain and Mertz, "New Method for Assessing Epidermal Wound Healing: The Effects of Triamcinolone Acetonide and Polyethelene Film Occlusion" <u>J. Invest. Dermatol.</u> 71:382-384 (1978)			
*	61	Eichhorn, E., "Restoring Function in Failing Hearts: The Effects of Beta Blockers" <u>American Journal of Medicine</u> 104:163-169 (1998)			
*	62	Falkenberg et al., "Expression of a functional proteinase inhibitor capable of accepting xylose: bikunin" <u>Arch Biochem Biophys</u> 387(1):99-106 (2001)			
*	63	Ferrara and Davis-Smyth., "The Biology of Vascular Endothelial Growth Factor." <u>Endocrine Reviews</u> . 18(1):4-25 (1997)			
*	64	Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells" <u>Biochem. & Biophys. Res. Comm.</u> 161(2):851-858 (1989)			
*	65	Ferrara et al., "Molecular and biological properties of the vascular endothelial growth factor family of proteins" <u>Endo. Rev.</u> 13:18-32 (1992)			
*	66	Ferrara et al., "The vascular endothelial growth factor family of polypeptides" <u>J. Cell. Biochem.</u> 47:211-218 (1991)			
*	67	Folkman and Shing, "Angiogenesis" <u>Journal of Biological Chemistry</u> 267:10931-10934 (1992)			
*	68	Folkman et al., "Induction of angiogenesis during the transition from hyperplasia to neoplasia" <u>Nature</u> 339(6219):58-61 (1989)			
*	69	Fouad et al. <u>J. Am. Coll. Cardiol.</u> 4:1500-1506 (1984)			
*	70	Garner, A., "Vascular Diseases" <u>Pathobiology of Ocular Disease. A Dynamic Approach</u> , Garner, A., Klintworth GK Eds., 2nd edition, NY:Marcel Dekker pps. 1625-1710 (1994)			
*	71	GBTRANS Database, Accession No. BC004140, "Serine portease inhibitor, Kunitz type 1 - Homo sapiens" (blast results) (Direct Submission March 1, 2001)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*	72	GENESEQ Patent Database, Accession No. P_B19553, "Human hepatocyte growth factor activator inhibitor-1 (HAI-1) - Homo sapiens" (blast results) (March 1, 2001)			
*	73	GENESEQ Patent Database, Accession No. P_W27368, "Hepatocyte growth factor activator inhibitor - Homo sapiens" (blast results) (Feb 26, 1997)			
*	74	GENESEQ Patent Database, Accession No. P_W63684, "Human secreted protein 4 - Homo sapiens" (blast results) (June 18, 1998)			
*	75	GENESEQ Patent Database, Accession No. P_W92653, "Human HAI-1 protein - Homo sapiens" (blast results) (Feb 9, 1999)			
*	76	Gohda et al., "Purification and Partial Characterization of Hepatocyte Growth Factor from Plasma of a Patient with Fulminant Hepatic Failure" <u>J. Clin. Invest.</u> 81:414-419 (1988)			
*	77	Good et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin" <u>Proc. Natl. Acad. Sci. USA</u> 87(17):6624-6628 (1990)			
*	78	Hamasuna et al., "Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells" <u>Int J Cancer</u> 93:339-3435 (2001)			
*	79	Harada et al., "Pressure Overload Induces Cardiac Hypertrophy in Angiotensin II Type 1A Receptor Knockout Mice" <u>Circulation</u> 97:1952-1959 (1998)			
*	80	Harrison et al., "Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis" <u>Circulation</u> 29:84-98 (1964)			
*	81	Hartford et al., "Diastolic Function of the Heart in Untreated Primary Hypertension" <u>Hypertension</u> 6:329-338 (1984)			
*	82	Homcy, C., "Signaling Hypertrophy: How Many Switches, How Many Wires" <u>Circulation</u> 97:1890-1892 (1998)			
*	83	Horak et al., "Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer" <u>Lancet</u> 340(8828):1120-1124 (1992)			
*	84	Houck et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA." <u>Mol. Endocrinol.</u> 5:1806-1814 (1991)			
*	85	Igawa et al., "Hepatocyte Growth Factor is a Potent Mitogen for Cultured Rabbit Renal Tubular Epithelial Cells" <u>Biochem. & Biophys. Res. Comm.</u> 174(2):831-838 (January 31, 1991)			
*	86	Inoue et al., "The Human Endothelin Family: Three Structurally and Pharmacologically Distinct Isopeptides Predicted by Three Separate Genes" <u>Proc. Natl. Acad. Sci. USA</u> 86:2863-2867 (April 1989)			
*	87	Inouye et al., "Failure of Antihypertensive Therapy with Diuretic, Beta-Blocking and Calcium Channel-Blocking Drugs to Consistently Reverse Left Ventricular Diastolic Filling Abnormalities" <u>Am. J. Cardiol.</u> 53:1583-1587 (1984)			
*	88	Ishikawa et al., "Identification of Angiogenic Activity and the Cloning and Expression of Platelet-Derived Endothelial Cell Growth Factor." <u>Nature.</u> 338:557-562 (1989)			
*	89	Jolovit et al., "Proviral Rearrangements and Overexpression of a New Cellular Gene (nov) in Myeloblastosis-Associated Virus Type 1-Induced Nephroblastomas" <u>Mol. Cell Biol.</u> 12:10-21 (1992)			
*	90	Kan et al., "Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE" <u>Biochem. & Biophys. Res. Comm.</u> 174(2):831-838 (January 31, 1991)			
*	91	Karmali et al., "Prostaglandins in breast cancer: Relationship to disease stage and hormone status" <u>Br. J. Cancer</u> 48:689-696 (1983)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
* 92	Kataoka et al., "Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment" <u>J Biol Chem</u> 275(51):40453-40462				
* 93	Katz, A.M., "Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart" <u>Trends Cardiovasc. Med.</u> 5(1):37-44 (1995)				
* 94	Keck et al., "Vascular Permeability Factor, An Endothelial Cell Mitogen Related to PDGF" <u>Science</u> 246:1309-1312 (1989)				
* 95	Keyt et al., "A Faster-Acting and More Potent Form of Tissue Plasminogen Activator." <u>Proc. Natl. Acad. Sci. USA</u> 91:3670-3674 (1994)				
* 96	Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" <u>Nature</u> 362:841-844 (1993)				
* 97	Klagsbrun and D'Amore, "Regulators of angiogenesis" <u>Ann. Rev. Physiol.</u> 53:217-239 (1991)				
* 98	Kramer et al., "Controlled Trial of Captopril on Chronic Heart Failure: A Rest and Exercise Hemodynamic Study" <u>Circulation</u> 67(4):807-816 (1983)				
* 99	Kurzrock et al., "LIF: Not Just a Leukemia Inhibitory Factor" <u>Endocrine Reviews</u> 12(3):208-217 (1991)				
*100	Lai et al., "Prostaglandin F _{2α} induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo" <u>Am. J. Physiol. (Heart Circ. Physiol.)</u> 271:H2197-H2208 (1996)				
*101	Lakso et al., "Targeted Oncogene Activation by Site-Specific Recombination in Transgenic Mice." <u>Proc. Natl. Acad. Sci. USA</u> 89:6232-6236 (Jul 1992)				
*102	Lau and Nathans, "Genes induced by serum growth factors" <u>The Hormonal Control of Gene Transcription</u> (Series: Molecular Aspects of Cellular Regulation), P. Cohen & J.G. Foulkes, NY:Elsevier Science Publishers Vol. 6:257-293 (1991)				
*103	Lavitrano et al., "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice" <u>Cell</u> 57:717-723 (1989)				
*104	Leung et al., "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen" <u>Science</u> 246:1306-1309 (1989)				
*105	Li et al., "Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality." <u>Cell</u> 69:915-926 (Jun 1992)				
*106	Lin et al., "Purification and characterization of a complex containing matriptase and a kunitz-type serine protease inhibitor from human milk" <u>J Biol Chem</u> 272(26):18237-18242 (1999)				
*107	Lo, C.W., "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations Without Tandem Insertions" <u>Mol. Cell Biol.</u> 3(10):1803-1814 (Oct 1983)				
*108	Lopez et al., "Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes" <u>Invest. Ophthalmol. Vis. Sci.</u> 37(5):855-868 (1996)				
*109	Lorell et al., "Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy" <u>Circulation</u> 65:499-507 (1982)				
*110	Louie and Edwards, "Hypertrophic Cardiomyopathy" <u>Prog. Cardiovasc. Dis.</u> 36:275-308 (1994)				
*111	Macchiarini et al., "Relation of neovascularisation to metastasis of non-small-cell lung cancer" <u>Lancet</u> 340(8812):145-146 (1992)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*112	Marian and Roberts, "Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy" <u>Circulation</u> 92:1336-1347 (1995)			
	*113	Maron et al., "Hypertrophic Cardiomyopathy: Interrelations of Clinical Manifestations, Pathophysiology, and Therapy" <u>New England J. of Medicine</u> 316:780-789 (1987)			
	*114	Massie, B., "Heart Failure 1997: a time to take stock" <u>Curr. Op. in Cardiology</u> 12:209-217 (1997)			
	*115	Matsumoto et al., "Hepatocyte Growth Factor is a Potent Stimulator of Human Melanocyte DNA Synthesis and Growth" <u>Biochem. & Biophys. Res. Comm.</u> 176(1):45-51 (April 15, 1991)			
	*116	Mattern et al., "Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma" <u>Brit. J. Cancer</u> 73(7):931-934 (1996)			
	*117	Melnyk et al., "Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth" <u>Cancer Research</u> 56(4):921-924 (1996)			
	*118	Metcalf, D., "Leukemia Inhibitory Factor--A Puzzling Polyfunctional Regulator" <u>Growth Factors</u> 7:169-173 (1992)			
	*119	Michalopoulos, G.K., "Liver regeneration: molecular mechanism of growth control" <u>FASEB Journal</u> 4:176-187 (1990)			
	*120	Miyazawa et al., "Molecular Cloning and Sequence Analysis of the cDNA for a Human Serine Protease Responsible for Activation of Hepatocyte Growth Factor" <u>Journal of Biological Chemistry</u> 268:10024-10028 (1993)			
	*121	Miyazawa et al., "Proteolytic Activation of Hepatocyte Growth Factor in Response to Tissue Injury" <u>Journal of Biological Chemistry</u> 269:8966-8970 (1994)			
	*122	Montesano et al., "Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor" <u>Cell</u> 67:901-908 (November 29, 1991)			
	*123	Morgan and Baker, "Cardiac Hypertrophy, Mechanical, Neural and Endocrine Dependence" <u>Circulation</u> 83:13-25 (1991)			
	*124	Naka et al., "Activation of Hepatocyte Growth Factor by Proteolytic Conversion of a Single Chain Form to a Heterodimer" <u>The Journal of Biological Chemistry</u> 267(28):20114-20119 (1992)			
	*125	Naldini et al., "Scatter Factor and Hepatocyte Growth Factor are Indistinguishable Ligands for the MET Receptor" <u>EMBO Journal</u> 10(10):2867-2878 (1991)			
	*126	Neuhaus et al., "Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator" <u>JACC</u> 14:1566-1569 (1989)			
	*127	Neuhaus et al., "Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Urokinase in Acute Myocardial Infarction: Results of the German Activator Urokinase Study (GAUS)" <u>J. Am. Coll. Cardiol.</u> 12:581-587 (1988)			
	*128	Nielsen et al., "Identification of Prokaryotic and Eukaryotic Signal Peptides and Prediction of Their Cleavage Sites" <u>Protein Engineering</u> 10(1):1-6 (1997)			
	*129	O'Brien et al., "Expression of <i>cyr61</i> , a Growth Factor-Inducible Immediate-Early Gene" <u>Mol. Cell Biol.</u> 10:3569-3577 (1990)			
	*130	O'Reilly et al., "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma" <u>Cell</u> 79(2):315-328 (1994)			
	*131	O'Reilly et al., "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth" <u>Cell</u> 88(2):277-285 (1997)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*132	O'Rourke and Reibel, "Effects of Adrenoceptor Blockade on Cardiac Hypertrophy and Myocardial Phospholipids" <u>P.S.E.M.B.</u> 200:95-100 (1992)				
*133	Palladino et al., "Characterization of the Antitumor Activities of Human Tumor Necrosis Factor- α and the Comparison with Other Cytokines: Induction of Tumor-Specific Immunity" <u>J. Immunol.</u> 138(11):4023-4032 (1987)				
*134	Pennica et al., "Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy" <u>Proc. Natl. Acad. Sci. USA</u> 92:1142-1146 (1995)				
*135	Piper et al., "Adult Ventricular Rat Heart Muscle Cells" <u>Cell Culture Techniques in Heart and Vessel Research</u> , H.M. Piper, Berlin:Springer-Verlag pps. 36-60 (1990)				
*136	Pollick, C., "Muscular subaortic stenosis, hemodynamic and clinical improvement after disopyramide" <u>New England J. of Medicine</u> 307(16):997-999 (1982)				
*137	Quivey et al., "Computerized Tomography in the Quantitative Assessment of Tumour Response" <u>Br. J. Cancer</u> 41:suppl. 4, 30 (1980)				
*138	Reddy et al., "Update on digoxin and other oral positive inotropic agents for chronic heart failure" <u>Curr. Op. in Cardiol.</u> 12:233-241 (1997)				
*139	REFSEQ Database, Accession No. NM_003710, "Hepatocyte growth factor activator inhibitor precursor" (blast results) (1998)				
*140	Rossi and Peres, "Effect of captopril on the prevention and regression of myocardial cell hypertrophy and interstitial fibrosis in pressure overload cardiac hypertrophy" <u>Am. Heart J.</u> 124:700-709 (1992)				
*141	Rubin et al., "A Broad-Spectrum Human Lung Fibroblast-Derived Mitogen is a Variant of Hepatocyte Growth Factor" <u>Proc. Natl. Acad. Sci. USA</u> 88:415-419 (1991)				
*142	Ryseck et al., "Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine-rich protein" <u>Cell Growth Differ.</u> 2:225-233 (1991)				
*143	Schwartz et al., "Molecular Basis of Familial Cardiomyopathies" <u>Circulation</u> 91:532-540 (1995)				
*144	Shahi et al., "Regression of hypertensive left ventricular hypertrophy and left ventricular diastolic function" <u>Lancet</u> 336:458-461 (1990)				
*145	Shahzad et al., "The molecular genetics of hypertrophic cardiomyopathy" <u>Curr. Opin. Cardiol.</u> 12:295-302 (1997)				
*146	Shimomura et al., "Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator" <u>European Journal of Biochemistry</u> 229:257-261 (1995)				
*147	Shimomura et al., "Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor" <u>Journal of Biological Chemistry</u> 272:6370-6376 (1997)				
*148	Simmons et al., "Identification of a phorbol ester-repressible v-src-inducible gene" <u>Proc. Natl. Acad. Sci.</u> 86:1178-1182 (1989)				
*149	Smith et al., "Rapid Ventricular Filling in Left Ventricular Hypertrophy: II. Pathological Hypertrophy" <u>J. Am. Coll. Cardiol.</u> 5:869-874 (1985)				
*150	The SOLVD Investigators, "Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure" <u>New England J. of Medicine</u> 325(5):293-302 (1991)				
*151	Spirito et al., "Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population" <u>New England J. of Medicine</u> 320:749-755 (1989)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	Group not yet assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*152	Spirito et al., "The Management of Hypertrophic Cardiomyopathy" <u>New England J. of Medicine</u> 336:775-785 (1997)			
	*153	Stoker et al., "Scatter Factor is a Fibroblast-Derived Modulator of Epithelial Cell Mobility" <u>Nature</u> 327:239-242 (May 21, 1987)			
	*154	Swissprot (SPROT) Database, SPT1_HUMAN, "Kunitz-type protease inhibitor 1 precursor - homo sapiens" (blast results) (Feb 27, 2001)			
	*155	Szlachcic et al., "Effect of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension" <u>Am. J. Cardiol.</u> 63:198-201 (1989)			
	*156	Tebbe et al., "Single-Bolus Injection of Recombinant Tissue-Type Plasminogen Activator in Acute Myocardial Infarction" <u>Am. J. Cardiol.</u> 64:448-453 (1989)			
	*157	Thierfelder et al., "α-Tropomyosin and Cardiac Troponin T Mutations Cause Familial Hypertrophic Cardiomyopathy: A Disease of the Sarcomere" <u>Cell</u> 77:701-712 (1994)			
	*158	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells." <u>Cell</u> 51:503-512 (Nov 1987)			
	*159	Thompson et al., "Effects of propranolol on myocardial oxygen consumption, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy" <u>Br. Heart J.</u> 44:488-498 (1980)			
	*160	Tischer et al., "Vascular Endothelial Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family." <u>Biochem. & Biophys. Res. Comm.</u> 165:1198-1206 (1989)			
	*161	Togo et al., "Host Organ Specifically Determines Cancer Progression" <u>Cancer Research</u> 55:681-684 (Feb. 1, 1995)			
	*162	Topol et al., "Comparison of Two Dose Regimens of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction" <u>Am. J. Cardiol.</u> 61:723-728 (1988)			
	*163	Topol, E.J., "Ultrathrombolysis" <u>J. Am. Coll. Cardiol.</u> 15:922-924 (1990)			
	*164	Van der Putten et al., "Efficient Insertion of Genes Into the Mouse Germ Line Via Retroviral Vectors" <u>Proc. Natl. Acad. Sci. USA</u> 82:6148-6152 (1985)			
	*165	von Heijne, G., "A new method for predicting signal sequence cleavage sites" <u>Nucl. Acids. Res.</u> 14(11):4683-4690 (1986)			
	*166	Wang et al., "Antibodies to Macrophage Stimulating Protein (MSP): Specificity, Epitope Interactions, and Immunoassay of MSP in Human Serum" <u>Journal of Leukocyte Biology</u> 54:289-295 (1994)			
	*167	Warren et al., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis" <u>J. Clin. Invest.</u> 95(4):1789-1797 (1995)			
	*168	Watkins et al., "Characteristics and prognostic implications of myosin missense mutations on familial hypertrophic cardiomyopathy" <u>New England J. of Medicine</u> 326:1108-1114 (1992)			
	*169	Watkins et al., "Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy" <u>Nat. Gen.</u> 11:434-437 (1995)			
	*170	Weber, K., "Extracellular Matrix Remodeling in Heart Failure: A Role for De Novo Angiotensin II Generation" <u>Circulation</u> 96:4065-4082 (1997)			
	*171	Weidner et al., "Scatter Factor: Molecular Characteristics and Effect on the Invasiveness of Epithelial Cells" <u>Journal of Cell Biology</u> 111:2097-2108 (November 1990)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1861R1C1	Serial No. not yet assigned
				Applicant Austin L. Gurney et al.	
				Filing Date 11 Dec 2003	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
	*172	Weidner et al., "Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma" <u>New England J. of Medicine</u> 324(1):1-8 (1991)			
	*173	Wigle et al., "Hypertrophic cardiomyopathy, clinical spectrum and treatment" <u>Circulation</u> 92:1680-1692 (1995)			
	*174	Winter, "Epidermal Regeneration Studied in the Domestic Pig" <u>Epidermal Wound Healing</u> , Maibach, H.I. and Rovee D.T., Chicago:Year Book Medical Publishers, Inc. pps. 71-112 (1972)			
	*175	Yanagisawa and Masaki, "Molecular Biology and Biochemistry of the Endothelins" <u>Trends Pharm. Sci.</u> 10:374-378 (September 1989)			
	*176	Yanagisawa et al., "A novel potent vasoconstrictor peptide produced by vascular endothelial cells" <u>Nature</u> 332:411-415 (1988)			
	*177	Zacharski, L.R., "Basis For Selection of Anticoagulant Drugs For Therapeutic Trials in Human Malignancy" <u>Haemostasis</u> . 16:300-320 (1986)			
	*178	Zapf et al., "Inhibition of the Action of Nonsuppressible Insulin-like Activity on the Isolated Rat Fat Cells by Binding to its Carrier Protein" <u>J. Clin. Invest.</u> 63:1077-1084 (1979)			
Examiner			Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					